Open access business models

Re: "Will open access work?"1 It is quite untrue to suggest that our report is biased because its funders all have an interest in the existing subscription/license journal publishing model. We deliberately engaged an impartial consultancy to carry out the work in order that the study should be entirely objective – we are perfectly willing to make the anonymized data freely available for others to analyze. And all three organizations have a strong interest in the Open Access model. The Asso

Written bySally Morris
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Re: "Will open access work?"1 It is quite untrue to suggest that our report is biased because its funders all have an interest in the existing subscription/license journal publishing model. We deliberately engaged an impartial consultancy to carry out the work in order that the study should be entirely objective – we are perfectly willing to make the anonymized data freely available for others to analyze. And all three organizations have a strong interest in the Open Access model. The Association of Learned and Professional Society Publishers (ALPSP) has issued its own position statement,2 and is following with great interest the large number of experiments being carried out, by members and others, on different types of Open Access publication.

The AAAS project on Science and Intellectual Property in the Public Interest, which provided support for the study, has as one of its goals, "developing models that facilitate open access to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies